lenalidomide + ketoconazole + hydrocortisone

lenalidomide + ketoconazole + hydrocortisone is a combination therapy evaluated by the Case Comprehensive Cancer Center for the treatment of castration-resistant prostate cancer (CRPC). Lenalidomide is a thalidomide analogue that functions as an immunomodulatory imide drug (IMiD), binding to the cereblon E3 ubiquitin ligase complex to induce the degradation of specific transcription factors and inhibit angiogenesis. Ketoconazole is a broad-spectrum antifungal that also serves as a potent inhibitor of the CYP17A1 enzyme, thereby blocking the synthesis of adrenal androgens that drive prostate cancer progression. Hydrocortisone is co-administered to replace endogenous cortisol production suppressed by ketoconazole. This specific regimen was studied in a Phase II trial (NCT00460031) to determine if the addition of lenalidomide could enhance the clinical activity of androgen synthesis inhibition in patients with hormone-refractory progressive disease.

Other names

Ketoconazole Plus LenalidomideLenalidomide, Ketoconazole, and Hydrocortisone